Vera Therapeutics, Inc.
General ticker "VERA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.6B (TTM average)
Vera Therapeutics, Inc. follows the US Stock Market performance with the rate: 8.5%.
Estimated limits based on current volatility of 3.9%: low 33.28$, high 35.83$
Factors to consider:
- Total employees count: 249 (+122.3%) as of 2025
- Company does not operate outside North America (retrieved using AI)
- Top business risk factors: Need additional capital, Regulatory and compliance, Commercialization failure, Product liability claims, Intellectual property risks
- Price in estimated range
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [27.26$, 67.23$]
- 2026-12-31 to 2027-12-31 estimated range: [17.50$, 46.38$]
Financial Metrics affecting the VERA estimates:
- Negative: with PPE of -11.4 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Negative: 0.07 < Interest expense per share per price, % of 0.22
- Negative: negative Industry operating income (median)
- Negative: Industry earnings per price (median), % of -15.99 <= 0
- Negative: Shareholder equity ratio, % of 82.28 > 81.92
- Negative: -0.37 < Inventory ratio change, % of 0
Short-term VERA quotes
Long-term VERA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $102.01MM | $167.17MM | $315.47MM |
| Operating Income | $-102.01MM | $-167.17MM | $-315.47MM |
| Non-Operating Income | $6.02MM | $15.02MM | $15.86MM |
| Interest Expense | $3.79MM | $7.63MM | $7.53MM |
| R&D Expense | $78.22MM | $126.17MM | $215.26MM |
| Income(Loss) | $-95.99MM | $-152.15MM | $-299.61MM |
| Taxes | $0.00MM | $0.00MM | $0.00MM |
| Net Income(Loss)* | $-95.99MM | $-152.15MM | $-299.62MM |
| Stockholders Equity | $101.69MM | $577.15MM | $604.52MM |
| Assets | $175.55MM | $655.68MM | $734.73MM |
| Operating Cash Flow | $-92.18MM | $-134.68MM | $-241.10MM |
| Capital expenditure | $0.06MM | $0.97MM | $0.63MM |
| Investing Cash Flow | $-39.43MM | $-425.03MM | $194.29MM |
| Financing Cash Flow | $133.54MM | $606.67MM | $308.90MM |
| Earnings Per Share** | $-2.25 | $-2.75 | $-4.66 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.